Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2023 · 10-Q
Revenue$337.90M$337.90M+39.3% vs Q2 2022 Net Income-$261.40M-$261.40MN/M vs Q2 2022 EPS Diluted-$5.16-$5.16N/M vs Q2 2022 Gross Profit$140,700,000+114.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$114,400,000N/M Free Cash Flowderived-$126,900,000N/M Margins · derivedGross margin41.6%+14.6 pt vs Q2 2022
Operating margin-86.7%−55.2 pt vs Q2 2022
Net margin-77.4%−55.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end